Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

The Quality Lowdown: Enforcement And Compliance During A Lingering Pandemic

Aug 16 2021

• By Bowman Cox

The Quality Lowdown

Related Content

Memo To File: How US FDA Decided Which Janssen Vaccine Drug Substance Batches Were OK To Use

Jun 15 2021

Lawsuit, Warning Letter Mark Return Of B. Cepacia As GMP Issue

Nov 18 2017

Emergent COVID-19 Vaccine Plant’s Quality Issues Draw Unusual Spotlight From US FDA Topsiders

Apr 22 2021

Merck’s COVID Manufacturing Deal With US Government Goes Well Beyond J&J Vaccine

Mar 03 2021

Drug Compounder Acquitted Of Murder In Fungal Meningitis Outbreak Case

Mar 23 2017

Special Counsel Finds US FDA’s Dismissal Of Inspection Concerns Unreasonable

Apr 05 2021

Florida Hand Sanitizer Firm’s Pandemic Experience: Recall Contaminated Product, Cease Production

Aug 10 2021

Related Companies

Eli Lilly and Company

Emergent BioSolutions, Inc.

AstraZeneca PLC

Janssen Pharmaceutical Cos.

Johnson & Johnson

Jubilant Pharma

Merck & Co., Inc.

Additional Topics

United States Compliance Enforcement Manufacturing Quality Coronavirus COVID-19 BioPharmaceutical

More from Compliance

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window